Finance

Danaher Taps M&A Well Again With Masimo Deal, Earnings Focus

Danaher is buying Masimo for $180 per share in cash, valuing Masimo at about $9.6 billion in equity and roughly $9.9 billion including debt. The deal will be financed with cash on hand and new debt, and it carries an 18x 2027 EBITDA multiple with a target to drop to 15x through synergies. The market reaction was swift: Masimo surged about 34% while Danaher slipped roughly 3-4%.

📅 February 17, 2026
⏱️ 2 min read
Danaher Taps M&A Well Again With Masimo Deal, Earnings Focus

Key Takeaways

  • Masimo to be acquired for $180 per share in cash, equity value about $9.6B.
  • Enterprise value around $9.9B, financed with cash on hand and new debt.
  • Transaction trades at ~18x 2027 EBITDA, with a goal to 15x after synergies.
  • Masimo up ~34% on the news; Danaher down ~3-4%.
  • Accretion of $0.15–$0.20 to adjusted diluted EPS in year one; about $0.70 in five years.

People Involved

  • No specific individuals mentioned

Entities Involved

  • Danaher Corp (DHR) Buyer in Masimo acquisition
  • Masimo Corp (MASI) Target in Danaher acquisition

MarketMoodz Analysis

For investors, the deal expands Danaher’s earnings power and adds a new patient-monitoring vertical, but it also introduces integration risk as two distinct business models must align under one portfolio. In a higher-rate debt environment, the 18x 2027 EBITDA multiple signals that buyers are willing to pay a premium for strategic assets if synergies materialize.

Historically, Danaher has used acquisitions to reshape its healthcare tools and diagnostics-focused portfolio, last narrowing its deal activity with the Abcam buyout for $5.7 billion in 2023. Masimo’s leadership in pulse oximetry and patient monitoring complements Danaher’s broad diagnostics footprint, but analysts flag Masimo as potentially outside Danaher’s traditional wheelhouse, tempering enthusiasm with caution about execution.

Next steps to watch include regulator approvals, integration milestones, and whether synergies deliver the targeted margin uplift. Investors should monitor guidance changes, Masimo’s long-term core revenue growth trajectory, and how higher debt costs influence Danaher’s ability to fund ongoing tuck-ins versus transformative deals.

Source: Original Article

Get AI-Powered Market Insights

Stay ahead of market-moving events with our real-time analysis and stock ratings.

Start Your Free Trial